Section 23 of the SF-86 is not one question with a seven-year window. It is seven questions, four of which turn on the word EVER, capitalised on the form. Most write-ups quote 23.1’s seven-year line and stop.

What follows describes what the form asks and what the guidelines say. It is not legal advice and does not tell anyone what to answer. Where our reading goes past the text, we flag it.

How many questions is Section 23, and how far back does each reach?

Seven, numbered 23.1 through 23.7. Questions 23.1, 23.2 and 23.5 use a seven-year window. Questions 23.3, 23.4, 23.6 and 23.7 carry no time limit; the form capitalises “EVER” in each. One more lifetime drug question sits outside Section 23, at 22.2.

Section 23 as published in the Standard Form 86, Revised November 2016 (OMB 3206-0005), form page 102:

Source: OPM, SF-86; windows verbatim. Questions 23.3 and 23.4 close “other than previously listed,” which governs where an episode goes, not whether it is disclosed.

Two details vanish in summaries. Question 23.2 is not a dealing question: “receiving” and “handling” sit beside trafficking. And 23.7, which many write-ups skip, asks about treatment you sought voluntarily.

Question 23.1 defines its own verb: use “includes injecting, snorting, inhaling, swallowing, experimenting with or otherwise consuming any drug or controlled substance.” Experimenting counts. Each entry asks first and most recent use, frequency, whether you held a clearance at the time, and “Do you intend to use this drug … in the future?” Dates take an “Est.” checkbox, as they do for an old address verifier.

The lifetime drug question that is not in Section 23

Question 22.2, in Section 22 (Police Record) on form page 99, asks whether you have “EVER had the following happen to you.” One bullet: “Have you EVER been charged with an offense involving alcohol or drugs?” No window.

An old charge can clear all seven Section 23 questions and still be reportable. No clearance at the time, no law-enforcement role, never ordered into treatment and never sought it, the use more than seven years back: Section 23 catches nothing, and 22.2 catches the charge. Section 22 adds that you report it “regardless of whether the record … has been sealed, expunged, or otherwise stricken,” excepting convictions expunged under 21 U.S.C. 844 or 18 U.S.C. 3607. Even 22.1’s seven-year citation bullet drops its small-fine exclusion when drugs were involved.

Why do four Section 23 questions have no time limit?

Partly on our reading. Guideline H treats use while cleared as its own disqualifying condition, which 23.3 tracks. But no Guideline H condition carries a time limit, so it cannot explain why 23.1 stops at seven years. For 23.4, 23.6 and 23.7 we found no matching text.

Security Executive Agent Directive 4, effective 8 June 2017, supersedes all previous national security adjudicative criteria. Guideline H sets seven disqualifying conditions. Condition 25(f) is the one 23.3 tracks word for word: “any illegal drug use while granted access to classified information or holding a sensitive position.” Note the limit: none of the seven carries a time limit, including 25(a), “any substance misuse,” which 23.1 collects on a seven-year window. Condition 25(g) matches 23.1’s future-intent field: “expressed intent to continue drug involvement and substance misuse.”

Question 23.4 is where the match breaks. SEAD 4 defines a “Sensitive Position” as one “within or in support of an agency.” A city police officer or a courtroom clerk is not that, and 23.4 asks them anyway: our reading is that the form casts wider than the guideline it feeds. Guideline H does not put treatment on the disqualifying side either: 25(e) reaches only “failure to successfully complete a drug treatment program,” and finishing one mitigates at 26(d).

The form collects facts for adjudicators to weigh; it does not decide the case. Mitigation sits in our Guideline H guide and the piece on prior use; consequences in our article on continuous-vetting suspensions.

What does the form promise about the answers you give?

Section 23 opens with a use-immunity sentence: truthful answers will not be used as criminal evidence against you. It is narrow. Truthful responses only, criminal proceedings only, nothing about eligibility, scoped to Section 23.

The preamble reads: “neither your truthful responses nor information derived from your responses … will be used as evidence against you in a subsequent criminal proceeding.”

Read the qualifiers. Truthful responses. Criminal proceeding. This section, which is why the sentence does not travel to a Section 22 answer. Nothing there limits what an adjudicator does with the information, and nothing covers a false answer. The same preamble applies Federal law “even though permissible under state laws.”

Did the April 2026 rescheduling change what Section 23 asks?

No. A final rule effective 28 April 2026 moved a narrow slice of marijuana to Schedule III. It changed no text in the SF-86, SEAD 4, or the Bond Amendment, and Schedule III is still controlled under Guideline H’s definition.

The headline version of this rule is wrong in both directions. The DEA/DOJ final rule at 91 FR 22714 reaches Schedule III only “to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to … dispense marijuana … for medical purposes.” The rule defines that licence as one held by a producer or dispensary, not a patient card.

Not everything outside Schedule III stayed in Schedule I. Hemp sits in no schedule, and products already rescheduled out of it, Marinol and Syndros among them, are untouched. The adult-use row is our reading, not a line the rule prints. The hemp row has a shelf life, and what changes is the test, not the number: footnote 11 says that from 12 November 2026 hemp is measured by “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent,” rather than the delta-9 figure used now. A THCA-rich or full-spectrum product that passes the delta-9 test can fail the total-THC one and become marijuana. A risk that is live already: FDA “does not certify levels of THC in CBD products,” the 2021 SecEA memo warns, so use may “result in a positive marijuana test,” Guideline H 25(b).

Rescheduling marijuana generally is a separate, unfinished matter. DEA noticed a hearing at 91 FR 22777, Docket DEA-1362, which opened 29 June 2026 and closed by 15 July. As of late July 2026 we found no final rule.

Here is what settles it. Guideline H defines its own term: “Controlled substance means any ‘controlled substance’ as defined in 21 U.S.C. 802,” which reaches every schedule, I through V. Rescheduling does not lift a drug out of Guideline H.

The standing marijuana guidance is still the Security Executive Agent memo of 21 December 2021, written when all marijuana was Schedule I. It tells agencies that prior recreational marijuana use “may be relevant to adjudications but not determinative,” routing the question into the whole-person concept. The same memo dates the forward-looking clock: agencies are “encouraged to advise” candidates to refrain from future marijuana use “upon initiation of the national security vetting process, which commences once the individual signs the certification contained in the Standard Form 86.” That is a recommendation to agencies, not a rule on applicants, but it marks where later use reads against 23.1’s intent field and, after an interim eligibility, as use while cleared. The memo reserved its own revision: the SecEA “may reexamine SEAD 4” should federal law change. As of late July 2026 we found none, which is our search result rather than proof none exists. Our earlier piece on reclassification predates the rule.

What do the guidelines say happens if you leave something out?

SEAD 4 draws a line most summaries erase. Refusal to cooperate or to answer is what the directive says “will normally result” in an unfavorable determination. A deliberate omission sits in the ordinary “may be disqualifying” list.

Inside the guidelines, “will normally result” appears exactly once, at Guideline E paragraph 15, attached to two things: “refusal, or failure without reasonable cause, to undergo or cooperate with security processing,” which expressly covers security forms and an authorized and required polygraph; and “refusal to provide full, frank, and truthful answers to lawful questions.”

Omission lives a paragraph later. Paragraph 16(a) lists “deliberate omission, concealment, or falsification of relevant facts from any personnel security questionnaire.” Note the adjective. Because the condition is built around deliberate conduct, a misremembered date and a concealed episode are not the same object. Paragraph 17(a) mitigates “prompt, good-faith efforts to correct the omission … before being confronted with the facts.”

The form states its penalty in three places, and only one carries a number. Its instructions, under “Penalties for Inaccurate or False Statements,” say “knowingly falsifying or concealing a material fact is a felony which may result in fines and/or up to five (5) years imprisonment.” The first question page makes you tick YES to having read that, acknowledging exposure to “denial or revocation of a security clearance, and/or removal and debarment from Federal Service.” The certification on form page 130 names no term: a false statement “can be punished by fine or imprisonment or both (18 U.S.C. 1001).” The statute sets five years as a maximum, eight where terrorism is involved. A maximum is not a prediction, and we found no published prosecution figure.

Is the Bond Amendment a lifetime bar after any drug use?

No. 50 U.S.C. 3343(b) is present tense: it bars granting or renewing a clearance for a covered person who “is an unlawful user of a controlled substance or an addict.” On our reading that is current status rather than past conduct.

Where recent use stops and “is an unlawful user” begins is defined nowhere we could find. Section 3343 defines “controlled substance” and “covered person” and imports “addict” from 21 U.S.C. 802(1); it never defines “unlawful user,” and neither does SEAD 4’s Appendix B. Treat the present-tense reading as ours, and the line’s location as a question for counsel.

Keep subsection (b) apart from (c). Subsection (b) concerns drugs, applies to clearances generally, and has no waiver provision. Subsection (c) turns on three cumulative facts, conviction of “a crime” in a U.S. court plus a sentence “exceeding 1 year” plus incarceration “for not less than 1 year,” alongside dishonorable discharge and mental incompetence; it reaches only SCI, special access programs and Restricted Data, and is waivable.

One qualifier cuts against that softer reading. SEAD 4’s Appendix B carries the bar into every adjudication under the directive: agency heads “are prohibited from granting or renewing national security eligibility” for an unlawful user or an addict, and “a meritorious waiver may not be authorized.” Present tense still decides who the bar catches; nothing softens it once it does.

The window everyone quotes covers three of seven questions

That is the finding. Seven years answers 23.1, 23.2 and 23.5; it is the wrong answer to 23.3, 23.4, 23.6 and 23.7, and no answer at all to 22.2. The April 2026 rescheduling was real and narrow, and moved not a comma of the form or the guidelines. The form is also mid-replacement: OPM’s notice at 87 FR 71700 promises the Personnel Vetting Questionnaire “a more limited scope of questioning regarding past use of marijuana,” and the FY2026 Q2 progress report dates “PVQ used for all vetting scenarios” to September 2027. The only reliable text is the one you are signing. Open the current SF-86 at opm.gov, read all seven questions at form page 102, then page 99 for 22.2, as you would read any section whose plain words outrank the summaries. Whichever form arrives, continuous vetting keeps checking.

Frequently Asked Questions

Does the seven-year window mean drug use from eight years ago never has to be reported?

Not as a general proposition. That limit belongs to 23.1, 23.2 and 23.5. Questions 23.3 (use while cleared), 23.4 (a law enforcement or courtroom role, or one “directly and immediately affecting the public safety”), 23.6 (ordered into treatment) and 23.7 (treatment sought voluntarily) have no time limit; the form prints “EVER” in each. Section 22 adds one more: 22.2 asks whether you have EVER been charged with an offense involving alcohol or drugs.

Marijuana moved to Schedule III in 2026. Does Section 23 still ask about it?

Yes. The 28 April 2026 rule reached marijuana in an FDA-approved drug product or under a state medical marijuana licence. Unlicensed bulk marijuana and synthetic THC remain Schedule I in the rule’s own words; adult-use retail product is Schedule I on our reading, sitting in neither Schedule III category. Hemp is not scheduled at all. Guideline H is keyed to 21 U.S.C. 802, which includes Schedule III.

If my state legalized it, does the SF-86 care?

The form answers this itself: its Section 23 preamble applies Federal law “even though permissible under state laws.” The 2021 Security Executive Agent memo tells agencies prior recreational use is “relevant to adjudications but not determinative,” directing them to SEAD 4’s whole-person analysis.

What is the difference between refusing to answer and omitting something?

SEAD 4 treats them differently. Paragraph 15 says refusal to cooperate, or to give full, frank and truthful answers, “will normally result in an unfavorable national security eligibility determination.” Deliberate omission appears at 16(a) among conditions that “may be disqualifying,” and 17(a) recognizes correction made before being confronted. None of this is legal advice; consult a clearance attorney.